Drug-induced hepatotoxicity: 2005

Journal of Clinical Gastroenterology

Volumn 39, Issue 4 SUPPL., 2005, Pages

  Maddrey, Willis C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acetaminophen; Drugs; Genetic polymorphism; Hepatotoxicity; Liver injury

Indexed keywords

BENZOQUINONE DERIVATIVE; HERBACEOUS AGENT; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; KAVA; MEVINOLIN; MINOCYCLINE; N ACETYL BENZOQUINONE IMIDE DERIVATIVE; NITROFURANTOIN; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENYTOIN; RETINOL; TETRACYCLINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE HEPATITIS; AGE; CHOLESTATIC HEPATITIS; GENETIC POLYMORPHISM; HUMAN; LIVER CELL DAMAGE; LIVER TOXICITY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEX; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC HEPATITIS;

EID: 15444368643     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000155548.91524.6e     Document Type: Review

References (55)

1. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia: Lippincott Williams & Wilkins, 1999.
2. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38:44-48.
3. Farrell GC. Drug-Induced Liver Disease. Edinburgh: Churchill-Livingstone, 1994.
4. Maddrey WC. Clinicopathologic patterns of drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. New York: Marcel Dekker, 2002:227-242.
5. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474-485.
6. Larrey D. Drug-induced liver diseases. J Hepatol. 2000;32:77-88.
7. Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf. 2002;1:159-172.
8. Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology. 2004;126:1477-1480.
9. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69:223-231.
10. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003; 348:529-537.
11. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA. 2001;286:2270-2279.
12. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-547.
13. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994; 271:992-998.
14. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001;33:308-310.
15. Maddrey WC. Isoniazid-induced liver disease. Semin Liver Dis. 1981;1: 77-84.
16. Watkins PB. Mechanisms of drug-induced liver disease. In: Schiff ER, Sorrell M, Maddrey WC, eds. Schiff's Diseases of the Liver, 9 ed. Philadelphia: Lippincott Williams & Wilkins, 2003:1129-1145.
17. Pessayre D, Fromenty B, Mansouri A, et al. Hepatotoxicity due to mitochondrial injury. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease, 1st ed. New York: Marcel Dekker, 2003:55-83.
18. Berson A, DeBeco V, Lettéron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114:764-774.
19. Beaune P, Dansette PM, Mansuy D, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA. 1987;84:551-555.
20. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22:767-773.
21. Schiodt FV, Rochling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med. 1997;337:1112-1117.
22. Rumack BH. Acetaminophen misconceptions. Hepatology. 2004;40:10-15.
23. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology. 2004;40:6-9.
24. Kaplowitz N. Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology. 2004;40:23-26.
25. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976;84:181-192.
26. Huang Y-S, Chem H-D, Su W-J, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37:924-930.
27. Huang Y-S, Chern H-D, Su W-J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35:883-889.
28. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:36-38.
29. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286:831-833.
30. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med. 2003;114:299-306.
31. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol. 2003;98:175-179.
32. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338:916-917.
33. Nagasaka S, Abe T, Kawakami A, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet Med. 2002;19:344-348.
34. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol. 2000;85:15E-19E.
35. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002;89:1374-1380.
36. de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24:584-591.
37. Downs JR, Clearfield MDO, Weis SDO, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
38. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287-1292.
39. Bhat G, Jordan J Jr, Sokalski SDO, et al. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998; 27:74-75.
40. Malcolm A, Heap TR, Eckstein RP, et al. Minocycline-induced liver injury. Am J Gastroenterol. 1996;91:1641-1643.
41. Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J. 1996;312:169-172.
42. Golstein PE, Deviere J, Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol. 1997;92:143-146.
43. Crosson J, Stillman MT. Minocycline-related lupus erythematosus with associated liver disease. J Am Acad Dermatol. 1997;36:867-868.
44. Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology. 1977;72:1348-1353.
45. Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med. 1994;154:1983-1984.
46. Escher M, Desmeules J. Hepatitis associated with Kava, a herbal remedy for anxiety. Br Med J. 2001;322:139.
47. Russmann S, Helbling A. Kava hepatotoxicity. Ann Intern Med. 2001; 135:68-69.
48. Russmann S, Barguil Y, Cabalion P, et al. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol. 2003;15:1033-1036.
49. Stickel F, Baumuller H-M, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol. 2003;39:62-67.
50. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedidne. 2003;10:440-446.
51. Whitton PA, Lau A, Salisbury A, et al. Kava lactones and the kava-kava controversy. Phytochemistry. 2003;64:673-679.
52. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by Kava Kava. J Toxicol Clin Toxicol. 2003;41:109-113.
53. Russell RM, Boyer JL, Bagheri SA, et al. Hepatic injury from chronic hypervitaminosis resulting in portal hypertension and ascites. N Engl J Med. 1974;291:435-440.
54. Geubels AP, De Galocsy C, Alves N, et al. Liver disease caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991;100:1701-1709.
55. Kowalski TE, Falestiny M, Furth E, et al. Vitamin A hepatotoxicity: a cautionary note regarding 25,000 IU supplements. Am J Med. 1994;97: 523-528.